Navigation Links
Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
Date:11/29/2007

Biologists, chemists, clinicians from Harvard, Stanford, University of Washington, the Scripps Research Institute, and Massachusetts General

Hospital partner with top investor groups Technology bypasses current debate on ethical use of embryonic stem cells by using pharmaceutical medicines to modulate stem cells inside the body

and via the use of 'reprogrammed' adult stem cells

SEATTLE, Nov. 29 /PRNewswire/ -- A group of the nation's most respected leaders in stem cell biology today announced formation of Fate Therapeutics, a new biotechnology company developing drugs to control cell fate. Fate will harness the healing power of adult stem cells by using small molecule drugs to modulate cells in vivo (in the body) and by reprogramming mature adult cells into stem cells.

"Fate's approach is the dawn of a new day in medicine," said Dr. Ben Shapiro, retired Executive Vice President of Worldwide Basic Research, Merck Research Laboratories, and a member of Fate's Science Advisory Board.

"Revolutionary advances in stem cell research have shifted the entire debate. We are proving that adult stem cell proliferation and differentiation can be modulated in the human body, and we now have the ability to induce pluripotent stem cells from adult human tissue rather than relying on the use of stem cells derived from embryos."

The company expects to have a lead adult stem cell modulating drug, in a cancer-related indication, enter the clinic in 2008.

Fate Therapeutics' revolutionary platform is two-fold

The Fate platform focuses on both regenerative and reprogramming medicine. The Fate regenerative medicine platform involves developing drugs that awaken adult stem cells in the body to repair damaged cells and tissues. The Fate reprogramming medicine platform involves developing drugs to reprogram mature adult cells into stem cells which when differentiated can become healthy heart, bone, brain o
'/>"/>

SOURCE Fate Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...24 Sigma-Aldrich Corpora...SDAQ OMX conference on Tuesday, December 1st at 1:...rties may listen via live audio broadcast over the...m a a ldrich.com/ . Users can click the "Webc...ma-Aldrich: Sigma-Aldrich is a leading Life Scie...
(Date:11/24/2009)...YKJAVIK, Iceland, November 24 /PRNewswire-FirstCal...announced the approval of all of its,"first day" m...ct of Delaware,(the "Bankruptcy Court"). deCODE la...r Chapter 11 of the United States Bankruptcy Code ...ssued by the Bankruptcy Court allow the company to...
(Date:11/24/2009)...f., Nov. 24 NeurogesX, I...focused on developing and commercializing novel pa...ony DiTonno, President and Chief Executive Officer... Jaffray Health Care Conference, to be held Decemb...ork, New York. ,, Mr. DiTonno and Stephen Ghig...
(Date:11/24/2009)...RNewswire/ -- Blue Marble Energy Corp. announced t...pment Authority (OPDA) were recently awarded $2 mi...italization Board (CERB) in a private/public partn...ochemical biorefinery in Lincoln County, WA. ,...evelopment of our biorefinery and bring over 70 gr...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...ust 28 Strong organic,growth continued in Q2 2008...development of Exiqon,s first molecular diagnostic... for year end launch., - Revenue in Q2 2008 incr...8 million, totaling DKK 44.5 million in the first ...ncreased by 239% on the same period last year to ...
...olcano Corporation,(Nasdaq: VOLC ), a leading man...d (IVUS), functional measurement (FM) and Optical ...hance the diagnosis and treatment,of coronary and ...ll be,participating in the Thomas Weisel Partners ...4., The presentation by Scott Huennekens, preside...
...ance, August 28 , - Hubert Sagnieres Appointed Ch...rectors of Essilor International today appointed H...ve alongside Xavier Fontanet,Chief Executive Offic..., A graduate of Ecole Centrale in Lille and holde...silor in 1989 as President of International,Market...
Other Biology Technology:Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited) 2Volcano Presentation at Thomas Weisel Conference to Be Webcast 2
(Date:11/26/2009)... at last worked out a way of using recordings of b...ulations. This is the first time sound recordings ...accurate estimates of bird species, populations. B...Ecological Society,s Journal of Applied Ecology ,...a major advance in our ability to monitor whale an...
(Date:11/26/2009)...in-resistant Staphylococcus Aureus ) and other dr...ow-temperature plasma prototype devices have been ... bactericidal cocktails. , Two prototype devices...on of healthy skin (e.g. hands and feet) in hospit...thal threat; and another to shoot bacteria-killing...
(Date:11/25/2009)..., firefighters, police officers and ambulance work...Trade Center complex. They battled to save people ...ivors, tackled fires and evacuated as many people ...ted 17,000 people. And making their jobs even hard...ned workers and their relatives jammed mobile netw...
Breaking Biology News(10 mins):Ecologists sound out new solution for monitoring cryptic species 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 1Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 2Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 3Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 4Frost 26amp 3B Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low Dose Contraceptive Patch 14508 5Grifols Breaks Ground on New National Testing Laboratory 14506 1Grifols Breaks Ground on New National Testing Laboratory 14506 2U S Food and Drug Administration Approves CRESTOR 28R 29 for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5525 1U S Food and Drug Administration Approves CRESTOR 28R 29 for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5525 2U S Food and Drug Administration Approves CRESTOR 28R 29 for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5525 3U S Food and Drug Administration Approves CRESTOR 28R 29 for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5525 4
...l be brought to the marketplace, giving laboratori... organisms. EMBLEM Technology Transfer GmbH (EMBLE...r Biology Laboratory (EMBL), announced today that ...leader Carl Zeiss to commercialize a new technolog...copy). , "Microscopes have to evolve to keep up wi...
...of Reproduction contains a report of some intrigui...i from one genus of fish were transplanted to enuc... offspring, cloned from nuclei of common carp and ...l to the nuclear donor species, Cyprinus carpio, i...er of vertebrae in the clones, however, was in the...
...nce and drug development : only "lucrative","marke...casions I,ve,seen very promising drugs candidates ...s to be made with it, even if millions would have,...this fate is to find,a drug candidate that affect ...fitable" one. PLoS Medecine has an article about a...
Other Biology News:The transparent organism: EMBLEM and Carl Zeiss give labs a unique look at life 2Finding Cures For Tropical Diseases: Is Open Source An Answer? 2
...reedom EVOlyzer is Tecans new Enzyme-Linked Immuno...mated microplate processing. Freedom EVOlyzer is a...ng and includes state-of-the art reader, washer an...ed EVOlyzer software. The Freedom EVOlyzer is avai...
...ins are polypeptide hormones which belong to the t... TGF- superfamily is a large group of extra-cellul...velopment, reproductive function and tumor formati...etic proteins, growth differentiation factors, AMH...
...read Plating Beads Sterile plating in just secon...rdous ethanol flaming, More uniform spreading and...le packaging: dispenser bottle for spreading 100 p...t and easiest way to spread cells on multiple plat...
...aboratories working in a regulated environment, Pi...software that automates gravimetric pipette calibr...eets todays regulatory compliance requirements. Pi...es a full security implementation, support for Ora...
Biology Products: